Bupivacaine extended release liposome injection does not prolong QTc interval in a thorough QT/QTc study in healthy volunteers

Journal of Clinical Pharmacology

Volumn 52, Issue 9, 2012, Pages 1441-1447

  Naseem, Asif ^a   Harada, Tomohiko ^a   Wang, Duolao ^b   Arezina, Radivoj ^a   Lorch, Ulrike ^a   Onel, Erol ^c   Camm, Alan John ^a   Taubel, Jorg ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c Pacira Pharmaceuticals Inc   (United States)

Author keywords

bupivacaine; clinical trial; EXPAREL; healthy subject; moxifloxacin; QTc

Indexed keywords

BUPIVACAINE; MOXIFLOXACIN; PLACEBO;

ABDOMINAL PAIN; ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG FORMULATION; DRUG INTOXICATION; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; HUMAN EXPERIMENT; INJECTION SITE ERYTHEMA; INJECTION SITE IRRITATION; INJECTION SITE PRURITUS; INJURY; MALE; NAUSEA; NEUROLOGIC DISEASE; NORMAL HUMAN; POSTOPERATIVE ANALGESIA; QT INTERVAL; QT PROLONGATION; SINGLE DRUG DOSE;

ADULT; ANESTHETICS, LOCAL; ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; BUPIVACAINE; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LIPOSOMES; LONG QT SYNDROME; MALE; QUINOLINES;

EID: 84866048651     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270011419853     Document Type: Article

References (17)

1. Concepcion M, Covino BG. Rational use of local anesthetics. Drugs. 1984 ; 54: 256-540
2. Huang YF, Pryor ME, Mather LE, Veering BT. Cardiovascular and central nervous system effects of intravenous levobupivacaine and bupivacaine in sheep. Anesth Analg. 1991 ; 86 (4). 797-804
3. Gristwood RW. Cardiac and CNS toxicity of levobupivacaine: strengths of evidence for advantage over bupivacaine. Drug Saf. 2002 ; 25 (3). 153-163
4. de La Coussaye JE, Bassoul BP, Albat B, et al. Succinylcholine does not worsen bupivacaine induced cardiotoxicity in pentobarbital anesthetized dogs. Can J Anaesth. 1992 ; 39: 192-197
5. Borgeat A, Ekatodramis G, Blumenthal S. Interscalene brachial plexus anesthesia with ropivacaine 5 mg/mL and bupivacaine 5 mg/mL: effects on electrocardiogram. Reg Anesth Pain Med. 2004 ; 29: 557-563
6. Bardsley H, Gristwood R, Baker H, Watson N, Nimmo W. A comparison of the cardiovascular effects of levobupivacaine and racbupivacaine following intravenous administration to healthy volunteers. Br J Clin Pharmacol. 1998 ; 46: 245-249
7. Foster RH, Markham A. Levobupivacaine: a review of its pharmacology and use as a local anesthetic. Drugs. 2000 ; 59: 551-579
8. Angst MS, Drover DR. Pharmacology of drugs formulated with DepoFoam: a sustained release drug delivery system for parenteral administration using multivesicular liposome technology. Clin Pharmacokinet. 2006 ; 45 (12). 1153-1176
9. Knudsen K, Beckman Suurküla M, Blomberg S, Sjövall J, Edvardsson N. Central nervous and cardiovascular effects of i.v. infusions of ropivacaine, bupivacaine and placebo in volunteers. Br J Anaesthesia. 1997 ; 78: 507-514
10. Owczuk R, Sawicka W, Wujtewicz MA, Kawecka A, Lasek J, Wujtewicz M. Influence of spinal anesthesia on corrected QT interval. Reg Anesth Pain Med. 2005 ; 30 (5). 548-552
11. International Conference on Harmonisation Step 4 Guideline ; 2005 London: European Medicines Agency ; 2005.
12. Camm AJ. Clinical trial design to evaluate the effects of drugs on cardiac repolarization: current state of the art. Heart Rhythm. 2005 ; 2 (2). S23 - S29
13. Morganroth J. A definitive or thorough phase 1 QT ECG trial as a requirement for drug safety assessment. J Electrocardiol. 2004 ; 37 (1). 25-29
14. Tornøe CW, Garnett CE, Wang Y, Florian J, Li M, Gobburu JV. Creation of a knowledge management system for QT analyses. J Clin Pharmacol. 2010 ;:
15. Dixon R, Job S, Oliver R, et al. Lamotrigine does not prolong QTc in a thorough QT/QTc study in healthy subjects. Br J Clin Pharmacol. 2008 ; 66 (3). 396-404
16. Strnadova C. The assessment of QT/QTc interval prolongation in clinical trials: a regulatory perspective. Drug Inf J. 2005 ; 39: 407-433
17. Wang D, Cheung YB, Arezina R, Taubel J, Camm AJ. A nonparametric approach to QT interval correction for heart rate. J Biopharm Stat. 2010 ; 20 (3). 508-522